KRAS and non-small cell lung carcinoma: After preclinical studies, results of early clinical trials recently demonstrated that pharmacological inhibition of KRAS G12C mutated protein is feasible, opening the possibility of a new targeted treatment for large subset of patients with advanced NSCLC [9,10,11,12,13,14,15].